Plain-English translation of NCT06396416 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Obesity research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether , a medication that helps with weight loss, can help people with advanced kidney disease lose weight safely. Participants will either receive the medication plus nutritional guidance and virtual coaching sessions, or continue with their usual kidney care. The study wants to see if this approach works before running a larger trial.
Many kidney transplant programs in Canada won't accept patients with obesity because of concerns about surgery complications. Losing weight is very hard when you have advanced kidney disease, especially because kidney disease diets are restrictive and exercise is often difficult. This trial is testing whether this medication could help people qualify for the lifesaving transplant they need.
You likely qualify if…
You likely don't qualify if…
If you're in the treatment group, you'll receive weekly injections of the medication for six months, adjusted gradually to reach the target dose. You'll also meet with a coach virtually once every four weeks to discuss nutrition and movement, tailored to your kidney disease needs. If you're in the usual care group, you'll continue your regular kidney and diabetes appointments without the medication or coaching. The entire study lasts about six months.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
Canada